Meeting
2020 ASCO Virtual Scientific Program
Phase I/II trial assessing hydroxychloroquine and itraconazole in women with advanced platinum-resistant epithelial ovarian cancer (EOC) (HYDRA-01).
Authors
Ainhoa Madariaga
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
Ainhoa Madariaga , Stefano Marastoni , Ilaria Colombo , Victoria Mandilaras , Michael Cabanero , Jeffrey Bruce , Swati Garg , Lisa Wang , Sarbjot Gill , Neesha C. Dhani , Valerie Bowering , Xuan Li , Amit M. Oza , Anthony M. Joshua , Stephanie Lheureux
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT03081702
Citation
J Clin Oncol 38: 2020 (suppl; abstr 6049)
DOI
10.1200/JCO.2020.38.15_suppl.6049
Abstract #
6049
Poster Bd #
220
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Breakthrough
MEKiAUTO: A multicenter phase 1 study of combination therapy with the MEK inhibitor, cobimetinib, immune checkpoint blockade, atezolizumab, and the autophagy inhibitor hydroxychloroquine (HCQ) in KRAS-mutated advanced malignancies.
First Author: Gulam Abbas Manji
Poster
2023 ASCO Annual Meeting
A phase 2 basket trial of ulixertinib (BVD-523) in combination with hydroxychloroquine in patients with advanced gastrointestinal malignancies harboring MAPK pathway mutations (BVD-523-HCQ).
First Author: Andrew H. Ko
Poster
2023 ASCO Annual Meeting
Interim results from a phase I/II study of duvelisib PI3Kδγ inhibitor and nivolumab in patients with advanced unresectable melanoma who have progressed on anti-PD1 therapy.
First Author: Jingxiao Jin
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A single-arm, phase II study of autophagy modulation using hydroxychloroquine in addition to encorafenib and cetuximab or panitumumab in metastatic BRAF-mutated colorectal cancer refractory to standard therapy.
First Author: Chetan Vakkalagadda